AVEO Pharmaceuticals (AVEO) & Its Competitors Critical Survey
AVEO Pharmaceuticals (NASDAQ: AVEO) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare AVEO Pharmaceuticals to similar businesses based on the strength of its analyst recommendations, profitability, earnings, risk, dividends, valuation and institutional ownership.
Earnings & Valuation
This table compares AVEO Pharmaceuticals and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AVEO Pharmaceuticals||$2.52 million||-$26.88 million||-4.13|
|AVEO Pharmaceuticals Competitors||$284.28 million||$34.29 million||78.43|
This table compares AVEO Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AVEO Pharmaceuticals Competitors||-5,311.45%||-433.95%||-39.53%|
Risk and Volatility
AVEO Pharmaceuticals has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, AVEO Pharmaceuticals’ competitors have a beta of 7.12, meaning that their average share price is 612% more volatile than the S&P 500.
Institutional and Insider Ownership
51.0% of AVEO Pharmaceuticals shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 4.7% of AVEO Pharmaceuticals shares are held by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a breakdown of recent ratings for AVEO Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AVEO Pharmaceuticals Competitors||852||3199||11603||231||2.71|
AVEO Pharmaceuticals presently has a consensus target price of $4.17, suggesting a potential upside of 42.21%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.96%. Given AVEO Pharmaceuticals’ competitors higher possible upside, analysts plainly believe AVEO Pharmaceuticals has less favorable growth aspects than its competitors.
AVEO Pharmaceuticals competitors beat AVEO Pharmaceuticals on 8 of the 12 factors compared.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.